| Project/Area Number |
23791092
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Fujita Health University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
NAGAI Hirokazu 国立病院機構名古屋医療センター, 臨床研究センター, 部長 (30360811)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 血液腫瘍学 / 多発性骨髄腫 / 比較効果研究 / メタアナリシス / 国際情報交換 / 国際情報交流、米国 |
|---|
| Research Abstract |
Currently available first-line therapies for untreated multiple myeloma consist of conventional chemotherapies, high-dose chemotherapies followed by autologous stem-cell transplantation, and novel agents-based therapies, which are selected on the basis of important clinical factors such as age, and biochemical, cytogenetic, and molecular markers. We performed systematic reviews and meta-analyses to evaluate comparative efficacy of these therapeutic strategies, and critically appraised the evidence on the prognostic factors.
|
